Skip to main content
Premium Trial:

Request an Annual Quote

BD Revenues Increase 8 Percent, but Profit Falls on $115M Clontech Charge

NEW YORK, Nov. 4 (GenomeWeb News) - Becton Dickinson today reported that total revenues increased 8 percent in the third quarter to $1.3 billion from $1.2 billion year over year.

 

Sales at BD's Biosciences unit were flat at $89 million.

 

BD spent $59 million on research and development in the quarter, up 12 percent from $52 million for the same quarter in 2003.

 

Net income receded to $67 million for the period from $161 million in the year-ago quarter. The decline reflected a $116 million charge relating to BD's plans to sell its Clontech unit.

BD did not disclose its cash position.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.